Rapid infusion rituximab changing practice for patient care

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Rituximab, an anti-CD20 monoclonal antibody, is crucial for treating non-Hodgkin's lymphoma.
• Intravenous rituximab administration typically involves prolonged infusion times (5-6 hours for the first infusion, 3-4 hours for subsequent infusions) due to potential infusion-related toxicities.
• Optimizing rituximab infusion protocols can improve patient comfort and healthcare resource utilization.

Observation:

• This study evaluated a shortened 90-minute infusion protocol for rituximab in non-Hodgkin's lymphoma patients.
• The first rituximab cycle followed standard prolonged infusion times (5-6 hours).
• Subsequent cycles were administered over 90 minutes (20% dose in 30 min, 80% in 60 min).

Findings:

• A total of 126 infusions were administered to 21 non-Hodgkin's lymphoma patients.
• The 90-minute rituximab infusion schedule was well-tolerated, with no observed Grade 3/4 infusion-related adverse events.
• The shortened infusion was deemed safe and effective for second and subsequent rituximab administrations.

Implications:

• Shortened rituximab infusions (90 minutes) are safe and well-tolerated for non-Hodgkin's lymphoma patients receiving subsequent cycles.
• This expedited protocol significantly reduces resource utilization within healthcare settings.
• The institution adopted the 90-minute rituximab infusion as routine practice, demonstrating its feasibility and benefits.